GE Healthcare has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Revolution CT platform.
First showcased at RSNA 2013, Revolution offers 16-cm whole-organ coverage, spatial resolution through the new Gemstone Clarity detector, and a new gantry designed to image at 0.28-sec rotation speed and tested to support rotation speeds up to 0.2 sec in the future, according to the vendor.
In addition, Revolution makes use of GE's adaptive statistical iterative reconstruction (ASIR) V next-generation technology, which also recently received FDA clearance. ASIR-V is designed to reduce noise levels, improve low-contrast detectability, and reduce dose by up to 82% for patients of all ages, GE said.
GE said it has also incorporated features designed to reduce patient anxiety, such as Whisper Drive, soft ambient lighting, personalized gantry display, and bore pattern. Fast and low-dose 70-kVp acquisitions can also be performed for sedation-free and minimal breath-hold pediatric studies, the company said.
Worldwide commercial shipments of Revolution CT are expected to begin this summer.
